Inclusion of a specific T cell epitope increases the protection conferred against foot-and-mouth disease virus in pigs by a linear peptide containing an immunodominant B cell site

Virology Journal

Volumn 9, Issue , 2012, Pages

  Cubillos, Carolina ^a   De La Torre, Beatriz G ^b   Bárcena, Juan ^a   Andreu, David ^b   Sobrino, Francisco ^a,c   Blanco, Esther ^a  

^a INIA   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

Author keywords

FMDV; Foot and mouth disease virus; Linear peptides; Pig; Swine; Vaccine

Indexed keywords

EPITOPE; FREUND ADJUVANT; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN VP1; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG SCREENING; EXPERIMENTAL PIG; FEVER; FOOT AND MOUTH DISEASE VIRUS; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; VACCINATION; VIRUS EXCRETION; VIRUS REPLICATION; VIRUS SHEDDING;

ANIMALIA; FOOT-AND-MOUTH DISEASE VIRUS; SUIDAE;

EID: 84858020968     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-6622416886     Document Type: Article

References (36)

1. The economics of foot and mouth disease. James AD Rushton J, Rev Sci Tech 2002 21 637 644 12523703 (Pubitemid 36080130)
2. Foot and mouth disease virus vaccines. Rodriguez LL Grubman MJ, Vaccine 2009 27 Suppl 4 90 D94 19837296
3. Incursions of foot-and-mouth disease virus into Europe between 1985 and 2006. Valarcher JF Leforban Y Rweyemamu M Roeder PL, Gerbier G Mackay DK, Sumption KJ Paton DJ, Knowles NJ,, Transbound Emerg Dis 2008 55 14 34 10.1111/j.1865-1682.2007.01010.x 18397506
4. Incidence and distribution of foot-and-mouth disease in Asia, Africa and South America; combining expert opinion, official disease information and livestock populations to assist risk assessment. Sumption K Rweyemamu M Wint W,, Transbound Emerg Dis 2008 55 5 13 10.1111/j.1865-1682.2007.01017.x 18397505
5. Review of the status of foot and mouth disease and approach to control/eradication in Europe and Central Asia. Leforban Y Gerbier G, Rev Sci Tech 2002 21 477 492 12523688 (Pubitemid 36080115)
6. Foot-and-Mouth disease situation worldwide and major epidemiological events in 2005-2006. http://www.fao.org/docs/eims/upload//225050/Focus-ON-1-07- en.pdf
7. FMD vaccines. Doel TR, Virus Res 2003 91 81 99 10.1016/S0168-1702(02) 00261-7 12527439 (Pubitemid 36078432)
8. Transmission pathways of foot-and-mouth disease virus in the United Kingdom in 2007. Cottam EM Wadsworth J, Shaw AE Rowlands RJ, Goatley L Maan S, Maan NS Mertens PP, Ebert K Li Y,, et al. PLoS Pathog 2008 4 1000050 10.1371/journal.ppat.1000050 18421380
9. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Grubman MJ, Biologicals 2005 33 227 234 10.1016/j.biologicals.2005.08.009 16289996 (Pubitemid 41743812)
10. Global FMD control-is it an option? Kitching P Hammond J Jeggo M Charleston B, Paton D Rodriguez L, Heckert R,, Vaccine 2007 25 5660 5664 10.1016/j.vaccine.2006.10.052 17126959 (Pubitemid 47039262)
11. The three-dimensional structure of foot-and-mouth disease virus at 2.9 A resolution. Acharya R Fry E, Stuart D Fox G, Rowlands D Brown F, Nature 1989 337 709 716 10.1038/337709a0 2537470 (Pubitemid 19064726)
12. Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Bittle JL Houghten RA, Alexander H Shinnick TM, Sutcliffe JG Lerner RA, Rowlands DJ Brown F, Nature 1982 298 30 33 10.1038/298030a0 7045684 (Pubitemid 12087468)
13. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. van der Burg SH Bijker MS Welters MJ Offringa R, Melief CJ,, Adv Drug Deliv Rev 2006 58 916 930 10.1016/j.addr.2005. 11.003 16979788 (Pubitemid 44709262)
14. Application of DIVA vaccines and their companion diagnostic tests to foreign animal disease eradication. Pasick J, Anim Health Res Rev 2004 5 257 262 10.1079/AHR200479 15984335
15. A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. Taboga O Tami C, Carrillo E Nunez JI, Rodriguez A Saiz JC, Blanco E Valero ML, Roig X Camarero JA,, et al. J Virol 1997 71 2606 2614 9060612 (Pubitemid 27119896)
16. Foot-and-mouth disease virus: a long known virus, but a current threat. Sobrino F Saiz M Jimenez-Clavero MA Nunez JI, Rosas MF Baranowski E, Ley V,, Vet Res 2001 32 1 30 10.1051/vetres:2001106 11254174 (Pubitemid 32155703)
17. Enhanced mucosal immunoglobulin A response and solid protection against foot-and-mouth disease virus challenge induced by a novel dendrimeric peptide. Cubillos C de la Torre BG Jakab A Clementi G, Borras E Barcena J, Andreu D Sobrino F, Blanco E,, J Virol 2008 82 7223 7230 10.1128/JVI.00401-08 18448530 (Pubitemid 351977739)
18. Identification of T-cell epitopes in nonstructural proteins of foot-and-mouth disease virus. Blanco E Garcia-Briones M Sanz-Parra A Gomes P, De Oliveira E Valero ML, Andreu D Ley V, Sobrino F,, J Virol 2001 75 3164 3174 10.1128/JVI.75.7.3164-3174.2001 11238843 (Pubitemid 32225880)
19. New approaches in vaccine development. Leclerc C, Comp Immunol Microbiol Infect Dis 2003 26 329 341 10.1016/S0147-9571(03)00018-3 12818620 (Pubitemid 37168471)
20. Foot-and-mouth disease virus peptide vaccines. Rowlands D, Foot-and-Mouth disease: Current perspectives Norfolk: Horizon Bioscience, Sobrino F, Domingo E, 2004 335 354
21. More than one reason to rethink the use of peptides in vaccine design. Purcell AW McCluskey J Rossjohn J,, Nat Rev Drug Discov 2007 6 404 414 10.1038/nrd2224 17473845 (Pubitemid 46696551)
22. Current strategies for subunit and genetic viral veterinary vaccine development. Brun A Barcena J Blanco E Borrego B, Dory D Escribano JM, Le Gall-Recule G Ortego J, Dixon LK,, Virus Res 2011 157 1 12 10.1016/j.virusres. 2011.02.006 21316403
23. DNA vaccines expressing B and T cell epitopes can protect mice from FMDV infection in the absence of specific humoral responses. Borrego B Fernandez-Pacheco P Ganges L Domenech N, Fernandez-Borges N Sobrino F, Rodriguez F,, Vaccine 2006 24 3889 3899 10.1016/j.vaccine.2006.02.028 16563575
24. A DNA vaccine encoding foot-and-mouth disease virus B and T-cell epitopes targeted to class II swine leukocyte antigens protects pigs against viral challenge. Borrego B Argilaguet JM, Perez-Martin E Dominguez J, Perez-Filgueira M Escribano JM, Sobrino F Rodriguez F, Antivir Res 2011 92 359 363 10.1016/j.antiviral.2011.07.017 21820470
25. The relationship between serum antibody titres and protection from foot and mouth disease in pigs after oil emulsion vaccination. Black L Francis MJ Rweyemamu MM Umebara O, Boge A,, J Biol Stand 1984 12 379 389 10.1016/S0092-1157(84)80062-1 6098583 (Pubitemid 15119428)
26. Protective immune response against foot-and-mouth disease. McCullough KC De Simone F, Brocchi E Capucci L, Crowther JR Kihm U, J Virol 1992 66 1835 1840 1312607
27. Immunology of Foot-and-Mouth disease. McCullough KC Sobrino F, Foot-and-Mouth disease: Current perspectives Norfolk: Horizon Bioscience, Sobrino F, Domingo E, 2004 173 222
28. Functional and structural aspects of the interaction of foot-and-mouth disease virus with antibodies. Mateu MG Verdaguer N, Foot-and-Mouth disease: Current perspectives Norfolk: Horizon Bioscience, Sobrino F, Domingo E, 2004 223 260
29. Serological and mucosal immune responses after vaccination and infection with FMDV in pigs. Eble PL Bouma A Weerdmeester K Stegeman JA, Dekker A,, Vaccine 2007 25 1043 1054 10.1016/j.vaccine.2006.09.066 17157418 (Pubitemid 44937453)
30. Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Jennings GT Bachmann MF, Curr Mol Med 2007 7 143 155 10.2174/156652407780059140 17346167 (Pubitemid 46488187)
31. Immunoregulation. O'Shea Jhon J, Nutman Thomas B, eLS John Wiley & Sons Ltd, Chichester 2001 http://www.els.net doi:10.1038/npg.els.0000952
32. The effects of gamma interferon on replication of foot-and-mouth disease virus in persistently infected bovine cells. Zhang ZD Hutching G, Kitching P Alexandersen S, Arch Virol 2002 147 2157 2167 10.1007/s00705-002-0867-6 12417950 (Pubitemid 36003322)
33. Guinea pig-adapted foot-and-mouth disease virus with altered receptor recognition can productively infect a natural host. Nunez JI Molina N Baranowski E Domingo E, Clark S Burman A, Berryman S Jackson T, Sobrino F,, J Virol 2007 81 8497 8506 10.1128/JVI.00340-07 17522230 (Pubitemid 47242822)
34. Innate immune defenses induced by CpG do not promote vaccine-induced protection against foot-and-mouth disease virus in pigs. Alves MP Guzylack-Piriou L Juillard V Audonnet JC, Doel T Dawson H, Golde WT Gerber H, Peduto N McCullough KC, Summerfield A,, Clin Vaccine Immunol 2009 16 1151 1157 10.1128/CVI.00018-09 19553550
35. Radial immuno-diffusion and serum-neutralisation techniques for the assay of antibodies to swine vesicular disease. Golding SM Hedger RS Talbot P,, Res Vet Sci 1976 20 142 147 178035
36. Detection of foot-and-mouth disease virus from culture and clinical samples by reverse transcription-PCR coupled to restriction enzyme and sequence analysis. Saiz M De La Morena DB, Blanco E Nunez JI, Fernandez R Sanchez-Vizcaino JM, Vet Res 2003 34 105 117 10.1051/vetres:2002059 12588687 (Pubitemid 36240375)